Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: Prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis

Catheterization and Cardiovascular Interventions

Volumn 59, Issue 4, 2003, Pages 459-462

  Sperling, Robert T ^a   Pinto, Duane S ^a   Ho, Kalon K L ^a   Carrozza Jr , Joseph P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Glycoproteins; Kidney; Pharmacokinetics; Revascularization

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CORONARY STENT; FEMALE; HEMODIALYSIS; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION;

AGED; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MALE; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RENAL DIALYSIS; TIME FACTORS;

EID: 0042165874     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10576     Document Type: Article

References (9)

1. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-1115.
2. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-1688.
3. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-542.
4. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation 1996;94:2083-2089.
5. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88:1512-1517.
6. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227.
7. Merck. Aggrastat package insert. West Point, PA: Merck; 2000.
8. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
9. Simon DI, Liu CB, Ganz P, et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Cathet Cardiovasc Intervent 2001;52:425-432.